MacroGenics Highlights Preliminary Clinical Results From Single Arm Study Of Lorigerlimab

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved

byBenzinga Newsdesk

February 13, 2023

1 minute read

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90)
Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial responses
Manageable overall safety profile observed across multiple expansion cohorts
- Company plans to initiate Phase 2 study in mCRPC in 2023M

Barclays Maintains Equal-Weight on Magna International, Lowers Price Target to $64

By Benzinga Newsdesk

May 3, 8:06 AM

Barclays analyst Brian Johnson maintains Magna International (NYSE:MGA) with a Equal-Weight and lowers the price target from $68 to $64.

MGA

JinkoSolar Announced Jiangxi Jinko to Go Through Registration Process with China Securities Regulatory Commission Prior to STAR Market IPO

By Charles Gross

September 30, 5:27 AM

JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS) provided updates on the status of the proposed initial public offering ("STAR Market IPO") and listing of the shares of its principal operating subsidiary, Jinko Solar Co., Ltd.

JKS

US To Discontinue COVID Testing for Incoming Air Travelers

By Akanksha Bakshi

June 10, 3:36 PM

An official claimed that the United States would withdraw a 17-month-old rule that people arriving in the country by air test negative for COVID-19, a move that comes after strong lobbying by airlines and the travel industry,

AAL

Facebook Exec Says Apple’s Approach To Tackling Child Sexual Abuse ‘Very Concerning’

By Madhukumar Warrier

August 9, 2:10 AM

Will Cathcart, the head of Facebook Inc.’s (NASDAQ: FB) WhatsApp instant messaging app, said that Apple Inc.’s (NASDAQ: AAPL) approach to tackling child sexual abuse is “wrong” and

AAPL

MacroGenics Highlights Preliminary Clinical Results From Single Arm Study Of Lorigerlimab

Related Posts

Barclays Maintains Equal-Weight on Magna International, Lowers Price Target to $64

JinkoSolar Announced Jiangxi Jinko to Go Through Registration Process with China Securities Regulatory Commission Prior to STAR Market IPO

US To Discontinue COVID Testing for Incoming Air Travelers

Facebook Exec Says Apple’s Approach To Tackling Child Sexual Abuse ‘Very Concerning’